Bruce Robinson, MD
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Keratinocyte Carcinoma
Basal Cell Carcinomas
Squamous Cell Carcinoma
Skin Cancer
Tirbanibulin ointment 1%
non-ablative fractional laser
PHASE1
PHASE2
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 100 participants |
| Masking : | NONE |
| Primary Purpose : | TREATMENT |
| Official Title : | Using Fractional Lasers and Tirbanibulin Ointment to Treat Keratinocyte Carcinomas |
| Actual Study Start Date : | 2025-05-16 |
| Estimated Primary Completion Date : | 2030-05 |
| Estimated Study Completion Date : | 2030-06 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Bruce Robinson, MD
New York, New York, United States, 10022